The easypod injection device allows automatic recording and transmission of adherence data from patients receiving recombinant human growth hormone (r-hGH; Saizen) to treat growth disorders. Through the easypod connect platform, healthcare professionals can access transmitted data and gain insights into adherence patterns. This analysis aimed to evaluate real-world adherence to r-hGH therapy administered via easypod at 1, 3, 6 12 and 24 months, plus overall data at 48 months in Latin American (LATAM) patients.
Data were downloaded on 15th February 2019 from 4,530 patients transmitting to easypod connect in nine LATAM countries (Argentina, Brazil, Chile, Colombia, El Salvador, Guatemala, Mexico, Nicaragua and Peru). The period of recorded data varied, according to individual's treatment length. Patient adherence (categorised as high [≥85%], intermediate [>56%84%] or low [≤56%]) was calculated as mg Saizen injected vs mg Saizen prescribed. Only data after the 10th injection registered on easypod were analysed. Puberty cut-off points were 10 years for girls and 12 years for boys.
In total, 4,459 patients recorded >10 injections. Overall, there were 2,719 patients (61.0 %), 1267 (28.4%) and 473 (10.6%) in the high, intermediate and low-adherence categories, respectively. A decrease in the proportion of patients in the high adherence category was observed over time, however, at month 24, 57.5% patients (422 of 734) were still in the high adherence category. At month 24, more females than males were in the high-adherence group (179 of 297 [60.3%] vs 243 of 437 [55.6%]), while a slightly higher proportion of younger patients recorded high-adherence data compared to older patients (95 of 159 [59.7%] vs 327 of 575 [56.9%]). The overall mean number of data transmissions was 5.10 [SD 9.87] and 4.87 [SD 9.39] in the high and intermediate-adherence categories respectively, compared with 2.52 [SD 3.45] in the low adherence category.
This is an update of the real-world analysis conducted in LATAM patients using easypodconnect, and evaluates 2-years of adherence data. Similarly, more girls than boys were in the high adherence group, while younger patients showed slightly higher adherence. Through our validated method of recording adherence, we can address an unmet need in r-hGH therapy. Patient/caregiver engagement via data transmission has the unique potential of providing information about data patterns of individual patients and may act as a foundation for care improvement.
19 - 21 Sep 2019
European Society for Paediatric Endocrinology